JP2017537124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537124A5 JP2017537124A5 JP2017530656A JP2017530656A JP2017537124A5 JP 2017537124 A5 JP2017537124 A5 JP 2017537124A5 JP 2017530656 A JP2017530656 A JP 2017530656A JP 2017530656 A JP2017530656 A JP 2017530656A JP 2017537124 A5 JP2017537124 A5 JP 2017537124A5
- Authority
- JP
- Japan
- Prior art keywords
- breast cancer
- composition
- use according
- patient
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006187 Breast cancer Diseases 0.000 claims description 21
- 208000026310 Breast neoplasm Diseases 0.000 claims description 21
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 15
- 229960004768 irinotecan Drugs 0.000 claims description 15
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 claims description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 3
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 7
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 230000003474 anti-emetic effect Effects 0.000 claims 4
- 239000002111 antiemetic agent Substances 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 4
- 229960005277 gemcitabine Drugs 0.000 claims 4
- 206010051290 Central nervous system lesion Diseases 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 2
- 239000000232 Lipid Bilayer Substances 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 2
- 239000002356 single layer Substances 0.000 claims 2
- 108091008039 hormone receptors Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089685P | 2014-12-09 | 2014-12-09 | |
| US62/089,685 | 2014-12-09 | ||
| PCT/US2015/064491 WO2016094402A1 (en) | 2014-12-09 | 2015-12-08 | Treatment of breast cancer with liposomal irinotecan |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020022400A Division JP2020073601A (ja) | 2014-12-09 | 2020-02-13 | リポソーマルイリノテカンによる乳がんの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537124A JP2017537124A (ja) | 2017-12-14 |
| JP2017537124A5 true JP2017537124A5 (enExample) | 2019-01-24 |
| JP7113619B2 JP7113619B2 (ja) | 2022-08-05 |
Family
ID=54979964
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530656A Active JP7113619B2 (ja) | 2014-12-09 | 2015-12-08 | リポソーマルイリノテカンによる乳がんの治療 |
| JP2020022400A Withdrawn JP2020073601A (ja) | 2014-12-09 | 2020-02-13 | リポソーマルイリノテカンによる乳がんの治療 |
| JP2022045463A Pending JP2022079545A (ja) | 2014-12-09 | 2022-03-22 | リポソーマルイリノテカンによる乳がんの治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020022400A Withdrawn JP2020073601A (ja) | 2014-12-09 | 2020-02-13 | リポソーマルイリノテカンによる乳がんの治療 |
| JP2022045463A Pending JP2022079545A (ja) | 2014-12-09 | 2022-03-22 | リポソーマルイリノテカンによる乳がんの治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20160346272A1 (enExample) |
| EP (1) | EP3229802A1 (enExample) |
| JP (3) | JP7113619B2 (enExample) |
| AU (1) | AU2015360761B2 (enExample) |
| HK (1) | HK1245133A1 (enExample) |
| WO (1) | WO2016094402A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PL3337467T3 (pl) | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| IL257149B2 (en) * | 2015-08-21 | 2024-11-01 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| MX382522B (es) | 2015-10-16 | 2025-03-13 | Ipsen Biopharm Ltd | Composiciones farmaceuticas estabilizantes de camptotecina. |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| MX2021001394A (es) * | 2018-08-05 | 2021-04-12 | Da Volterra | Metodo para mejorar la eficacia de un agente anticanceroso. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI283575B (en) * | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| UA86063C2 (ru) | 2004-05-03 | 2009-03-25 | Хермес Біосайенсез, Інк. | Липосомы для снабжения лекарств |
| US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| US20070219268A1 (en) * | 2006-03-16 | 2007-09-20 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| JP2013531068A (ja) * | 2010-07-19 | 2013-08-01 | バイパー サイエンシズ，インコーポレイティド | ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法 |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| WO2014113167A1 (en) * | 2012-12-14 | 2014-07-24 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
| PL3337467T3 (pl) * | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| IL257149B2 (en) * | 2015-08-21 | 2024-11-01 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| MX382522B (es) * | 2015-10-16 | 2025-03-13 | Ipsen Biopharm Ltd | Composiciones farmaceuticas estabilizantes de camptotecina. |
-
2015
- 2015-12-08 JP JP2017530656A patent/JP7113619B2/ja active Active
- 2015-12-08 EP EP15813999.8A patent/EP3229802A1/en not_active Withdrawn
- 2015-12-08 HK HK18104815.5A patent/HK1245133A1/zh unknown
- 2015-12-08 WO PCT/US2015/064491 patent/WO2016094402A1/en not_active Ceased
- 2015-12-08 AU AU2015360761A patent/AU2015360761B2/en not_active Ceased
- 2015-12-09 US US14/964,571 patent/US20160346272A1/en not_active Abandoned
-
2019
- 2019-12-11 US US16/711,072 patent/US20200360367A1/en not_active Abandoned
-
2020
- 2020-02-13 JP JP2020022400A patent/JP2020073601A/ja not_active Withdrawn
-
2022
- 2022-03-22 JP JP2022045463A patent/JP2022079545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537124A5 (enExample) | ||
| ES2424476T3 (es) | Nanopartículas cargadas con fármaco antitumoral quimioterápico | |
| JP2015523355A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| WO2011066684A1 (zh) | 伊立替康或盐酸伊立替康脂质体及其制备方法 | |
| JP2018184465A5 (enExample) | ||
| BR112012011485B1 (pt) | Forma de dosagem e cápsula para tratar náusea e vômito | |
| TWI749091B (zh) | 脂質體調配物 | |
| ES2956013T3 (es) | Formulación de equinomicina, método de producción y método de uso de la misma | |
| JP2018035162A5 (enExample) | ||
| EP3861987A1 (en) | Combination medicine comprising drug-encapsulating liposome composition and platinum preparation | |
| CN109771663B (zh) | 一种酸响应性抗癌纳米药物的制备及应用 | |
| JP7015237B2 (ja) | 腫瘍の成長を抑制する方法 | |
| JP2019516693A5 (enExample) | ||
| TW202207904A (zh) | 用於治療癌症及癌症抗藥性之脂質體調配物 | |
| JP2012522730A (ja) | 多糖リポソーム、その調製法及びその使用 | |
| JP2017520620A5 (enExample) | ||
| CN116514797B (zh) | 美托哌丙嗪的新型多晶型形式 | |
| WO2001083020A1 (en) | Antineoplastic platinum therapeutic method and composition | |
| JP2024526791A (ja) | リポソーム製剤の調製方法 | |
| JP6080837B2 (ja) | 療法的治療 | |
| JP2018516964A (ja) | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 | |
| CN109419773B (zh) | 复合纳米脂质给药系统及其对妇科肿瘤的治疗作用 | |
| EP3687498A1 (en) | Parenteral formulation comprising siponimod | |
| CN108135878A (zh) | 卡巴他赛及其治疗癌症的用途 |